Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors

Lynn G Feun, Angela Marini, Howard Landy, Arnold Markoe, Deborah O Heros, Carlos Robles, Cristina Herrera, Niramol Savaraj

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

CPT-11 is a potent inhibitor of topoisomerase I and has shown antitumor activity in brain xenografts and in clinical trials in recurrent/ progressive malignant glioma. VM-26 and VP-16 are topoisomerase II inhibitors and have also shown activity in phase II trials. We performed a phase II trial of intravenous CPT-11 (125 mg/m2) followed 24 h later by VM-26 (125 mg/m2). VP-16 (125 mg/m2) was later substituted for VM-26 due to drug shortage. For patients on anticonvulsants, the starting dose for all drugs was 150 mg/m2). Drugs were given weekly for 3 weeks followed by 1-week rest. Twenty-five patients were entered into the study. Three patients (12%) had improvement in CAT/MRI brain scans (95% confidence interval 3-31%). Fatigue and myelosuppression, mainly leukopenia, were the main toxicities. This combination of the topoisomerase I inhibitor CPT-11 followed by the topoisomerase II inhibitor, VM-26 or VP-16, has shown modest antitumor activity comparable to that reported for each drug singly. Myelosuppression is the main toxicity when topoisomerase I and II inhibitors are combined together.

Original languageEnglish
Pages (from-to)177-181
Number of pages5
JournalJournal of Neuro-Oncology
Volume82
Issue number2
DOIs
StatePublished - Apr 1 2007

Fingerprint

irinotecan
Teniposide
Etoposide
Topoisomerase I Inhibitors
Topoisomerase II Inhibitors
Brain Neoplasms
Clinical Trials
Pharmaceutical Preparations
Leukopenia
Brain
Heterografts
Glioma
Anticonvulsants
Fatigue
Magnetic Resonance Imaging
Confidence Intervals

Keywords

  • Brain tumor
  • Chemotherapy
  • CPT-11
  • VM-26
  • VP-16

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. / Feun, Lynn G; Marini, Angela; Landy, Howard; Markoe, Arnold; Heros, Deborah O; Robles, Carlos; Herrera, Cristina; Savaraj, Niramol.

In: Journal of Neuro-Oncology, Vol. 82, No. 2, 01.04.2007, p. 177-181.

Research output: Contribution to journalArticle

Feun, Lynn G ; Marini, Angela ; Landy, Howard ; Markoe, Arnold ; Heros, Deborah O ; Robles, Carlos ; Herrera, Cristina ; Savaraj, Niramol. / Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors. In: Journal of Neuro-Oncology. 2007 ; Vol. 82, No. 2. pp. 177-181.
@article{cb0e0a65606c40c98a2485fd7de8bc11,
title = "Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors",
abstract = "CPT-11 is a potent inhibitor of topoisomerase I and has shown antitumor activity in brain xenografts and in clinical trials in recurrent/ progressive malignant glioma. VM-26 and VP-16 are topoisomerase II inhibitors and have also shown activity in phase II trials. We performed a phase II trial of intravenous CPT-11 (125 mg/m2) followed 24 h later by VM-26 (125 mg/m2). VP-16 (125 mg/m2) was later substituted for VM-26 due to drug shortage. For patients on anticonvulsants, the starting dose for all drugs was 150 mg/m2). Drugs were given weekly for 3 weeks followed by 1-week rest. Twenty-five patients were entered into the study. Three patients (12{\%}) had improvement in CAT/MRI brain scans (95{\%} confidence interval 3-31{\%}). Fatigue and myelosuppression, mainly leukopenia, were the main toxicities. This combination of the topoisomerase I inhibitor CPT-11 followed by the topoisomerase II inhibitor, VM-26 or VP-16, has shown modest antitumor activity comparable to that reported for each drug singly. Myelosuppression is the main toxicity when topoisomerase I and II inhibitors are combined together.",
keywords = "Brain tumor, Chemotherapy, CPT-11, VM-26, VP-16",
author = "Feun, {Lynn G} and Angela Marini and Howard Landy and Arnold Markoe and Heros, {Deborah O} and Carlos Robles and Cristina Herrera and Niramol Savaraj",
year = "2007",
month = "4",
day = "1",
doi = "10.1007/s11060-006-9261-7",
language = "English",
volume = "82",
pages = "177--181",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Clinical trial of CPT-11 and VM-26/VP-16 for patients with recurrent malignant brain tumors

AU - Feun, Lynn G

AU - Marini, Angela

AU - Landy, Howard

AU - Markoe, Arnold

AU - Heros, Deborah O

AU - Robles, Carlos

AU - Herrera, Cristina

AU - Savaraj, Niramol

PY - 2007/4/1

Y1 - 2007/4/1

N2 - CPT-11 is a potent inhibitor of topoisomerase I and has shown antitumor activity in brain xenografts and in clinical trials in recurrent/ progressive malignant glioma. VM-26 and VP-16 are topoisomerase II inhibitors and have also shown activity in phase II trials. We performed a phase II trial of intravenous CPT-11 (125 mg/m2) followed 24 h later by VM-26 (125 mg/m2). VP-16 (125 mg/m2) was later substituted for VM-26 due to drug shortage. For patients on anticonvulsants, the starting dose for all drugs was 150 mg/m2). Drugs were given weekly for 3 weeks followed by 1-week rest. Twenty-five patients were entered into the study. Three patients (12%) had improvement in CAT/MRI brain scans (95% confidence interval 3-31%). Fatigue and myelosuppression, mainly leukopenia, were the main toxicities. This combination of the topoisomerase I inhibitor CPT-11 followed by the topoisomerase II inhibitor, VM-26 or VP-16, has shown modest antitumor activity comparable to that reported for each drug singly. Myelosuppression is the main toxicity when topoisomerase I and II inhibitors are combined together.

AB - CPT-11 is a potent inhibitor of topoisomerase I and has shown antitumor activity in brain xenografts and in clinical trials in recurrent/ progressive malignant glioma. VM-26 and VP-16 are topoisomerase II inhibitors and have also shown activity in phase II trials. We performed a phase II trial of intravenous CPT-11 (125 mg/m2) followed 24 h later by VM-26 (125 mg/m2). VP-16 (125 mg/m2) was later substituted for VM-26 due to drug shortage. For patients on anticonvulsants, the starting dose for all drugs was 150 mg/m2). Drugs were given weekly for 3 weeks followed by 1-week rest. Twenty-five patients were entered into the study. Three patients (12%) had improvement in CAT/MRI brain scans (95% confidence interval 3-31%). Fatigue and myelosuppression, mainly leukopenia, were the main toxicities. This combination of the topoisomerase I inhibitor CPT-11 followed by the topoisomerase II inhibitor, VM-26 or VP-16, has shown modest antitumor activity comparable to that reported for each drug singly. Myelosuppression is the main toxicity when topoisomerase I and II inhibitors are combined together.

KW - Brain tumor

KW - Chemotherapy

KW - CPT-11

KW - VM-26

KW - VP-16

UR - http://www.scopus.com/inward/record.url?scp=33947250740&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947250740&partnerID=8YFLogxK

U2 - 10.1007/s11060-006-9261-7

DO - 10.1007/s11060-006-9261-7

M3 - Article

C2 - 17051317

AN - SCOPUS:33947250740

VL - 82

SP - 177

EP - 181

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 2

ER -